Our Partnerships
The MDC works in partnership with many academic and biotech industries to supply patented technologies to Oxford researchers. These new technologies are clinically accredited diagnostics, and are a result of partnerships with:
- Base Genomics – Supplying patented TAPS methylation assays
- Illumina – Supplying next generation sequencing platform support
- Oxford Nanopore – Supplying hand-held diagnostic whole genome sequencing technology for applications in Chronic Lymphocytic Leukaemia, Acute Myeloid Leukaemia, Acute Lymphocytic Leukaemia and haemoglobinopathies
- Adaptive Biotech – Only UK site, based within the OMDC in Oxford, licensed to supply of measurable residual disease, T-Cell Receptor and B-Cell Receptor clonality assays
- Genomics England – Supplying whole genome sequencing technology
- Oxford Genomics Centre – supplying high-throughput, whole genome & next generation sequencing
- Mologic – supplying COVID-19 antibody testing technology
We also have access to patented technology, developed in part by the OMDC, which include:
- Non-invasive Prenatal Testing ® – foetal DNA analysis
- AlexaPath – imaging of tumour samples in Africa